Niraparib (Zejula) 100 mg capsules changing to tablets

What is happening?

Following Medsafe approval, GlaxoSmithKline (the supplier) advises that Zejula capsules will be changing to tablets. Medsafe has reviewed the new formulation and found that the tablets meet New Zealand standards of safety, quality and efficacy. 

Affected products

• Chemical: Niraparib
• Presentation: Cap 100 mg
• Brand: Zejula
• Wastage claimable 

Pack size: 56

• Pharmacode: 2635232 
• Subsidy: $8929.84

Pack size: 84

• Pharmacode: 2635240
• Subsidy: $13393.50

Schedule listing for Zejula(external link)

People taking Zejula should not notice a difference

The tablets have the same active ingredient in the same dose. They will work in your body the same way. You should continue to take the tablets the same way as the capsules.

When is this happening?

1 November 2024

The 84-tablet blister pack was listed on the Schedule. People can expect to start being dispensed the tablets during November.

1 August 2025

The 56-tablet blister pack of Zejula tablets will be listed on the Schedule. Based on current usage, we expect people to start being dispensed the tablets during September 2025.

Delisting of capsules

We have no set date for delisting the capsules. We will allow time for all the capsules to be dispensed and claimed for.

Who to contact

People who take niraparib should talk to a health care professional they trust, such as their doctor or pharmacist., if they have questions about this change. Pharmac cannot comment on anyone's individual clinical circumstances.

If you have questions about the funding or supply of this medicine, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)